Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Whitehawk Therapeutics (WHWK) FCF Margin (2018 - 2025)

Historic FCF Margin for Whitehawk Therapeutics (WHWK) over the last 6 years, with Q1 2025 value amounting to 173.76%.

  • Whitehawk Therapeutics' FCF Margin rose 2071900.0% to 173.76% in Q1 2025 from the same period last year, while for Sep 2025 it was 667.34%, marking a year-over-year decrease of 4422700.0%. This contributed to the annual value of 235.55% for FY2024, which is 257400.0% up from last year.
  • Per Whitehawk Therapeutics' latest filing, its FCF Margin stood at 173.76% for Q1 2025, which was up 2071900.0% from 210.51% recorded in Q4 2024.
  • In the past 5 years, Whitehawk Therapeutics' FCF Margin registered a high of 8802.5% during Q1 2021, and its lowest value of 842.74% during Q1 2022.
  • For the 5-year period, Whitehawk Therapeutics' FCF Margin averaged around 329.6%, with its median value being 217.87% (2022).
  • Per our database at Business Quant, Whitehawk Therapeutics' FCF Margin crashed by -96452400bps in 2022 and then soared by 4561900bps in 2023.
  • Whitehawk Therapeutics' FCF Margin (Quarter) stood at 89.1% in 2021, then crashed by -145bps to 217.87% in 2022, then grew by 24bps to 165.35% in 2023, then dropped by -27bps to 210.51% in 2024, then grew by 17bps to 173.76% in 2025.
  • Its last three reported values are 173.76% in Q1 2025, 210.51% for Q4 2024, and 220.12% during Q3 2024.